Jade Biosciences (JBIO) said late Friday it has closed its public offering of 11.5 million shares, including the full exercise of an over-allotment option, raising $172.5 million for the clinical-stage biotechnology company.
The company said net proceeds will be used among others for clinical trials, preclinical studies, working capital and other general corporate purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.